Skip to main content


Global Public Health

Global Public Health  

Throughout our more than 130-year history, Johnson & Johnson has had a legacy of coming to the aid of local and global communities during times of crisis, from natural disasters to health outbreaks. We believe we have a responsibility to step in and invest in solutions for global public health crises and we are immensely proud to be making such significant contributions.                   

COVID-19 has had an unprecedented impact on the world as we know it. The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to rapid scientific progress toward treatment and prevention measures for this global health crisis.

Since January 2020, Johnson & Johnson has been working directly with Governments and health authorities to help end this fast-moving pandemic, and we will continue to bring our full resources and best scientific minds to combat it - not just because we can, because we must.  

Beyond COVID-19, as a leader in the field of global health, we remain focused on redefining the treatment paradigm for infectious diseases affecting global communities, most notably including diseases like tuberculosis (TB) and Ebola.

We are also working with the not-for-profit Drugs for Neglected Diseases initiative (DNDi) on the pre-clinical programme for a potential new treatment against parasites that cause elephantiasis and river blindness — two of the most difficult-to-treat neglected tropical diseases (NTDs).

International Health Partners (IHP)- Medicines for those in need

We are proud to partner with International Health Partners (IHP) to donate products to crisis-hit communities and help eradicate suffering caused by poor access to medicine. IHP help vulnerable people by overseeing, co-ordinating and delivering strategic medical product donations to those in desperate need of healthcare around the world.

Explore More


Looking After Our Environment




Our Partnerships




Our Focus



CP-322384 | June 2022